Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 168

1.

A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT).

Turpie AG, Bauer KA, Davidson BL, Fisher WD, Gent M, Huo MH, Sinha U, Gretler DD; EXPERT Study Group.

Thromb Haemost. 2009 Jan;101(1):68-76.

PMID:
19132191
2.

Fondaparinux for prevention of venous thromboembolism in major orthopedic surgery.

Tran AH, Lee G.

Ann Pharmacother. 2003 Nov;37(11):1632-43. Review.

PMID:
14565815
3.

Prevention of venous thromboembolism with new oral anticoagulants versus standard pharmacological treatment in acute medically ill patients: a systematic review and meta-analysis.

Albertsen IE, Larsen TB, Rasmussen LH, Overvad TF, Lip GY.

Drugs. 2012 Sep 10;72(13):1755-64. doi: 10.2165/11635630-000000000-00000. Review.

PMID:
22876779
4.
5.

Venous thromboembolism prophylaxis: role of factor xa inhibition by fondaparinux.

Turpie AG.

Surg Technol Int. 2004;13:261-7. Review.

PMID:
15744699
6.

Fondaparinux: a new antithrombotic agent.

Cheng JW.

Clin Ther. 2002 Nov;24(11):1757-69; discussion 1719. Review.

PMID:
12501872
7.
8.
9.

Clinical experience with ximelagatran in orthopaedic surgery.

Eriksson B.

Drugs. 2004;64 Suppl 1:27-35. Review.

PMID:
15586625
10.

Total knee replacement and chemical thromboprophylaxis: current evidence.

Nikolaou VS, Desy NM, Bergeron SG, Antoniou J.

Curr Vasc Pharmacol. 2011 Jan;9(1):33-41. Review.

PMID:
21044024
11.
12.

Prevention of venous thromboembolism following orthopaedic surgery: clinical potential of direct thrombin inhibitors.

Eriksson BI, Dahl OE.

Drugs. 2004;64(6):577-95. Review. Erratum in: Drugs. 2004;64(8):912.

PMID:
15018589
13.
14.

Setting a standard for venous thromboembolism prophylaxis.

Turpie AG.

Am J Health Syst Pharm. 2001 Nov 1;58 Suppl 2:S18-23. Review.

PMID:
11715835
15.

Oral direct Factor Xa inhibitors versus low-molecular-weight heparin to prevent venous thromboembolism in patients undergoing total hip or knee replacement: a systematic review and meta-analysis.

Neumann I, Rada G, Claro JC, Carrasco-Labra A, Thorlund K, Akl EA, Bates SM, Guyatt GH.

Ann Intern Med. 2012 May 15;156(10):710-9. doi: 10.7326/0003-4819-156-10-201205150-00421. Epub 2012 Mar 12. Review.

PMID:
22412038
16.

Venous thromboembolism following total knee replacement.

Choi BY, Huo MH.

J Surg Orthop Adv. 2007 Spring;16(1):31-5. Review.

PMID:
17371645
17.

Pentasaccharide Org31540/SR90107A clinical trials update: lessons for practice.

Turpie AG.

Am Heart J. 2001 Aug;142(2 Suppl):S9-15. Review.

PMID:
11479485
18.

Apixaban. After hip or knee replacement: LMWH remains the standard treatment.

[No authors listed]

Prescrire Int. 2012 Sep;21(130):201-2, 204. Review.

PMID:
23016247
19.

[Rivaroxaban (Xarelto): efficacy and safety].

Rosencher N, Arnaout L, Chabbouh T, Bellamy L.

Ann Fr Anesth Reanim. 2008 Dec;27 Suppl 3:S22-7. doi: 10.1016/S0750-7658(08)75143-8. Review. French.

PMID:
19185784
20.

Preclinical and clinical characteristics of rivaroxaban: a novel, oral, direct factor Xa inhibitor.

Laux V, Perzborn E, Kubitza D, Misselwitz F.

Semin Thromb Hemost. 2007 Jul;33(5):515-23. Review.

PMID:
17629849
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk